| Aug 1 |
Lexicon Pharmaceuticals GAAP EPS of -$0.17 beats by $0.02, revenue of $1.65M misses by $1.79M
|
| Aug 1 |
Lexicon: Q2 Earnings Snapshot
|
| Aug 1 |
Lexicon Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Jul 31 |
Lexicon Pharmaceuticals Q2 2024 Earnings Preview
|
| Jul 25 |
Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024
|
| Jul 18 |
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
|
| Jul 17 |
FDA Accepts Lexicon's (LXRX) NDA for Type I Diabetes Drug
|
| Jul 16 |
Lexicon gains as diabetes therapy undergoes FDA review
|
| Jul 16 |
Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission
|
| Jul 15 |
New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart Failure
|
